BCAX · CIK 0002023658
What Bicara Therapeutics Inc. told the SEC could break it.
Bicara's disclosures are those of a single-asset, pre-revenue biotech whose entire value rests on one drug, ficerafusp alfa. Its prospects hinge on FDA, Health Canada and EMA approval of that candidate, and it flags trade-policy risk to its offshore supply chain — a September 2025 announced 100% tariff on brand-name or patented drugs (currently on hold) plus IRA pricing pressure. Having generated no revenue since its 2018 inception and run significant operating losses, it depends on continued capital-market access (including a $161.8 million February 2026 offering), relies entirely on third-party manufacturers, many outside the U.S., for all of its drug substance and product, and is significantly influenced by board-affiliated principal stockholders Biocon, RA Capital and TPG.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA/EMA approval dependence and proposed 100% tariff on branded/patented drugshigh
Bicara's future depends on FDA/Health Canada/EMA approval of ficerafusp alfa, and a September 2025 announced 100% tariff on brand-name/patented drugs (currently on hold) plus IRA pricing pressures could materially harm its offshore-manufacturing supply chain and prospects.
“in September 2025, the current administration also announced a 100% tariff on brand-name or patented drugs unless pharmaceutical companies expand their manufacturing operations in the U.S. Although the pharmaceutical tariff is currently on hold, this could have a material adverse effect on our supply chain and business prospects as well as the larger biopharmaceutical industry.”
SEC filing →As of 2026
Liquidity & debt
- no revenue since 2018 inception; significant losses; dependence on financingmedium
Bicara has generated no revenue since its December 2018 inception and incurs significant operating losses and negative cash flows; it funds operations via equity (IPO, ATM, the $161.8M February 2026 offering) and remains dependent on capital-market access to advance ficerafusp alfa.
“Since our inception in December 2018, we have not generated any revenue from any sources and have incurred significant operating losses and negative cash flows from operations.”
SEC filing →As of 2026
Other disclosures
- concentrated control by board-affiliated stockholders (Biocon, RA Capital, TPG); single-asset dependencemedium
Bicara's value depends on its single lead asset ficerafusp alfa, and principal stockholders affiliated with its board — Biocon, RA Capital and TPG LSA — can significantly influence corporate actions (director elections, mergers, asset sales), whose interests may diverge from other holders.
“certain of our principal stockholders, including Biocon, RA Capital and TPG LSA, are affiliated with members of our board of directors. The interests of these stockholders may not be the same as or may even”
SEC filing →As of 2026
Supplier concentration
- reliance on third-party manufacturers (many outside U.S.) for all drug substance/productmedium
Bicara relies entirely on third-party manufacturers — many located outside the United States — for the drug substance and final drug-product formulation of all its product candidates used in clinical and preclinical work, and intends to rely on third parties for commercial supply, exposing it to CM capacity, quality and regulatory risk.
“We currently rely on and engage third-party manufacturers to provide all of the drug substance and the final drug product formulation of all of our product candidates that are being used in our clinical trials and preclinical studies.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Biocon
“We are required on a calendar quarterly basis to deliver any additional materials or know-how relating to the product up until a mid-single digit anniversary from the effective date of the Biocon Agreement.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch